CA2457595A1 - Procede de production d'anticorps ex-vivo - Google Patents

Procede de production d'anticorps ex-vivo Download PDF

Info

Publication number
CA2457595A1
CA2457595A1 CA002457595A CA2457595A CA2457595A1 CA 2457595 A1 CA2457595 A1 CA 2457595A1 CA 002457595 A CA002457595 A CA 002457595A CA 2457595 A CA2457595 A CA 2457595A CA 2457595 A1 CA2457595 A1 CA 2457595A1
Authority
CA
Canada
Prior art keywords
composition according
composition
antigen
antibodies
egg yolk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002457595A
Other languages
English (en)
Inventor
Sveinbjoern Gizurarson
Jann Hau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lyfjathroun Hf Biopharmaceuticals
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2457595A1 publication Critical patent/CA2457595A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique à administrer à des espèces aviaires, en particulier de la volaille, dans leur eau de boisson ou leur alimentation, ou à projeter par aérosols sur les poules. Cette composition se compose d'un excipient comprenant un mono-/di-, ester-/étherglycéride conjugué à des groupes polymères solubles dans l'eau, sélectionnés à partir de polyéthylèneglycol contenant 2 à 30 unités de polyoxyéthylène, un antigène et éventuellement une toxine bactérienne, de préférence, du CTB. Cette composition présente une grande utilité pour la production d'anticorps dans le jaune d'oeuf. Les glycérides conjugués permettent d'augmenter la production d'anticorps ex-vivo dans le jaune d'oeuf, en réduisant le stress des animaux et les procédures invasives.
CA002457595A 2001-08-16 2002-08-16 Procede de production d'anticorps ex-vivo Abandoned CA2457595A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS6051 2001-08-16
IS6051 2001-08-16
PCT/DK2002/000539 WO2003016350A1 (fr) 2001-08-16 2002-08-16 Procede de production d'anticorps ex-vivo

Publications (1)

Publication Number Publication Date
CA2457595A1 true CA2457595A1 (fr) 2003-02-27

Family

ID=36809427

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002457595A Abandoned CA2457595A1 (fr) 2001-08-16 2002-08-16 Procede de production d'anticorps ex-vivo

Country Status (6)

Country Link
US (1) US20040241310A1 (fr)
EP (1) EP1423430A1 (fr)
JP (1) JP2005509598A (fr)
AU (1) AU2002333194B2 (fr)
CA (1) CA2457595A1 (fr)
WO (1) WO2003016350A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163787A1 (en) * 2002-02-25 2005-07-28 Lyfjathroun Hf, Biopharmaceutical Immunological adjuvant
US20050063940A1 (en) * 2002-02-25 2005-03-24 Sveinbjorn Gizurarson Bioadhesive agent
US6855332B2 (en) 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
AU2006285850A1 (en) * 2005-08-29 2007-03-08 Japan Science And Technology Agency Antibody produced using ostrich and method for production thereof
JP5305427B2 (ja) * 2007-01-11 2013-10-02 公立大学法人大阪府立大学 インフルエンザウイルスに対する抗体の産生方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US434540A (en) * 1890-08-19 Method of ornamenting circular dies or articles
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5753228A (en) * 1992-08-25 1998-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Method of treating parasitosis by the enteral administration of hyperimmune hen egg yolk antibodies
IT1255895B (it) * 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
US5403582A (en) * 1993-01-21 1995-04-04 Nippon Zeon Co., Ltd. Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
US5814321A (en) * 1995-11-30 1998-09-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Oil adjuvant vaccine and method for preparing same
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
US6142559A (en) * 1998-11-20 2000-11-07 Steelcase Development Inc. Seating product
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1034792A1 (fr) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Administration par voie intranasale de vaccins à base de polyosides de Pneumococcus
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent

Also Published As

Publication number Publication date
WO2003016350A1 (fr) 2003-02-27
EP1423430A1 (fr) 2004-06-02
JP2005509598A (ja) 2005-04-14
US20040241310A1 (en) 2004-12-02
AU2002333194B2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
AU8459898A (en) Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant
Bowersock et al. Vaccine delivery to animals
Bowersock et al. Oral vaccination with alginate microsphere systems
EP0937462A1 (fr) Compositions de vaccin à administration par la muqueuse
CN1296416A (zh) 佐剂组合物
US20100221223A1 (en) Immune response induction method
HUT69935A (en) Vaccines containing non-ionic surfactant vesicles
JP2011190278A (ja) 粘膜体表面に接触させてワクチン抗原を包含する物質の効果を調節する新規非抗原性粘膜アジュバント処方
KR101501583B1 (ko) 리포펩티드 및 폴리(ｉ:ｃ)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물
Klinguer et al. Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens
US6890540B1 (en) Vaccine formulation
AU2002333194B2 (en) A method of producing antibodies ex-vivo
US20080226709A1 (en) Phospholipid membrane preparation
ES2346441T3 (es) Composiciones y procedimientos para activar una inmunidad innata y alergica.
AU2002333194A1 (en) A method of producing antibodies ex-vivo
AU769390B2 (en) Vaccine composition
JP2004508424A (ja) 免疫調節調剤物
US20050163787A1 (en) Immunological adjuvant
WO2002053183A1 (fr) Vaccin contre l'hantavirus renfermant un adjuvant
Gizurarson et al. Intranasal vaccination: pharmaceutical evaluation of the vaccine delivery system and immunokinetic characteristics of the immune responses
Piganelli Development of enteric protected vaccines for aquaculture
JP2004182655A (ja) 医薬品組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued